linjc16/ctgov huggingface dataset:
Correlation Endoscopic View of Airway Obstruction With RRa in OSA Patients Under DEX Monitored With SedLine EEG

Study Overview
=================
Brief Summary
-----------------
Patients with obstructive sleep apnea (OSA) could have several anatomical causes of obstruction. A sleep endoscopy study is a technique to help determine the anatomical cause of OSA. This study will be using standard of care practice and infuse dexmedetomidine (DEX) to induce sleep. The goals of the study are to (1) confirm airway obstruction with endoscopic view and correlate that with Acoustic Respiratory Rate (RRa) signal at the moment of airway obstruction, and (2) characterize the EEG signals when subjects are under DEX sedation alone.

Official Title
-----------------
Correlation of Endoscopic View of Airway Obstruction With RRa Signal in OSA Patients Under Dexmedetomidine Anesthesia Monitored With SedLine EEG

Conditions
-----------------
Obstructive Sleep Apnea (OSA)

Intervention / Treatment
-----------------
* Device: SedLine EEG
* Device: RRa monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients more than 18 years old with American Society of Anesthesiologists (ASA) classification of I, II, or III. Patients undergoing sedation for sleep endoscopy with DEX alone, and possible surgical follow-up. Exclusion Criteria: ASA classification higher than III. Any deformities or diseases that may prevent application of SedLine (Masimo Sedation Monitoring) or RAM (Masimo Rainbow Acoustic Monitoring) sensors with a proper fit Inability to obtain any physiological, vital, demographics and real time anaesthesia data Subjects who have known intolerance to any of the drugs to be used according to the study protocol Subjects deemed not suitable for study at the discretion of the Principal Investigator.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Evaluation Group<br>All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring | Device: SedLine EEG<br> <br> Device: RRa monitoring<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Subjects in Which Electroencephalogram (EEG) Signals is Collected | Subjects enrolled into the study will have the SedLine sensor placed on the subject to collect EEG signals. | One visit | 
| Number of Subjects in Which Acoustic Respiratory Rate (RRa) Signals is Collected | All subjects enrolled into the study will receive the RAM sensor in order to records RRa signals. | One visit |
Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children

Study Overview
=================
Brief Summary
-----------------
The objective is evaluation of GoCheck Kids, a smartphone application ('App'), for use as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs).

Detailed Description
-----------------
Detection of amblyopia risk factors using photo screening app in children of ages from 12 months to 8 years

Official Title
-----------------
Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children

Conditions
-----------------
Amblyopia

Intervention / Treatment
-----------------
* Device: App Vision Screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 12 months to 8 years inclusive. Informed consent given by parent or legal guardian. Exclusion Criteria: - History of ocular surgery and any condition that would preclude the ability of the investigator to obtain a reliable image and measurement

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Refractive Error<br> | Device: App Vision Screening<br>* Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of amblyopia risk factors detected by Photorefraction | Identification of risk factors compared to gold standard cycloplegic refraction | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with gaze error identified by photo screening | Detection of gaze error compared to cover test examination results | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amblyopia, Myopia, Hyperopia, Risk Factors, Amblyopia Risk Factors, Smartphone Application (App), Photoscreening, Vision Screening, Mobile Vision Screening, Vision Screening App, Preschool children, Objective vision screening
Observational Study of Drug Naive Diabetes Receiving Insulin Therapy

Study Overview
=================
Brief Summary
-----------------
A multi-centre, open-label trial to investigate the efficacy and possible mechanism of Continuous Subcutaneous Insulin Infusion treatment in patients with drug naive type 2 diabetes.

Official Title
-----------------
Observational Study of Drug Naive Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: Insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: for type 2 diabetes: Male or female age ≧ 25 years and ≦75 years old HbA1c ≧8.0% durg naive for normal controls： Male or female age ≧ 25 years and ≦75 years old Normal glucose tolerance confirmed by oral glucose tolerance test Exclusion Criteria: Islet antibody positive Athletes, has a history of skeletal muscle injury ( trauma or surgery ), skeletal muscle wasting diseases ( such as mitochondrial myopathy, muscular atrophy, etc ) Acute infection(such as cute upper respiratory infection, acute pneumonia) long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs consists with other endocrine diseases pregnancy cancer use of antibiotics in 3 months chronic digestive inflammations magnetic resonance imaging contraindications

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 2 Diabetes<br>drug naive Type 2 Diabetes received insulin therapy | Drug: Insulin<br>* Continuous Subcutaneous Insulin Infusion<br>|
| normal control<br>healthy volunteers as normal control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating immunity cell profiles | profiles of circulating immunity cells such as T cells | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skeletal muscle parameter | skeletal muscle parameters in magnetic resonance imaging | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insulin, drug naive
A Comparison of Beverages Consumed Within a Meal to Satiation on Meal-time Food Intake and Post-meal Appetite and Glycemic Response in Healthy Young Adults

Study Overview
=================
Brief Summary
-----------------
The objective of the current study is to determine the effects of an ad libitum intake of 1% milk, fruit juice, regular cola, diet cola and water, as part of a pizza meal, on meal food intake, appetite and postprandial blood glucose in healthy men and women. We hypothesize that 1% milk will reduce food intake and result in better post-meal glycemic response compared to the other beverages.

Conditions
-----------------
Obesity, Hyperglycemia

Intervention / Treatment
-----------------
* Other: Nutritional Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men and women age 20-30 years BMI between 20-24.9 kg/m^2 Exclusion Criteria: breakfast skippers diabetes or any metabolic diseases lactose intolerance or allergies to milk taking medications

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1% Milk<br> | Other: Nutritional Intervention<br>* Ad libitum amounts of beverage at a meal<br>|
| Experimental: Regular Cola<br> | Other: Nutritional Intervention<br>* Ad libitum amounts of beverage at a meal<br>|
| Experimental: Diet cola<br> | Other: Nutritional Intervention<br>* Ad libitum amounts of beverage at a meal<br>|
| Experimental: Orange juice<br> | Other: Nutritional Intervention<br>* Ad libitum amounts of beverage at a meal<br>|
| Placebo Comparator: Water<br> | Other: Nutritional Intervention<br>* Ad libitum amounts of beverage at a meal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food Intake | Measurement of energy intake during an ad libitum test meal | 2 hours |
Image Fusion PET, CT and 3D-ultrasound Examinations

Study Overview
=================
Brief Summary
-----------------
CT-examinations are used in computer programs which are used in the planning of external radiation of cancers in the anal canal. In CT the structures of the anal canal are hardly visible. 3D-ultrasound examinations offer a better visualisation of normal and pathological structures of the anal canal. The description of the tumour made from the 3D-ultrasound examination is used in the planning of the external radiation. PET-CT is used to visualise tumour activity also in lymp nodes. The hypothesis of the study is that image fusion of PET, CT and 3D-ultrasound will offer better visualisation of tumour and hereby more accurate diagnostics and treatment.

Official Title
-----------------
Image Fusion PET, CT and 3D-ultrasound Examinations in Treatment of Anal Cancer

Conditions
-----------------
Anal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically verified cancer of the anal canal Exclusion Criteria: Pregnancy Unability to cooperate to radiation therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Program to fuse 3D ultrasound and PET/CT data |  | april 2009 |
Sub-Cutaneous Insulin in Hyperglycaemic Emergencies

Study Overview
=================
Brief Summary
-----------------
Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay.

Detailed Description
-----------------
This is a randomised trial concerning patients presenting in A & E with a diabetic emergency, either a Diabetic Ketoacidosis (DKA) or a Hyperosmolar Non-Ketotic Coma (HONC). Once informed consent has been given, each patient will receive standard intravenous treatment. They will also receive a daily sub-cutaneous bolus of either a long-acting insulin or a placebo. Blood will be taken at regular intervals to analyse the rate of fall of glucose and normalisation of blood pH.

Official Title
-----------------
The Use of a Long-Acting Sub-Cutaneous Insulin Analogue in the Management of Hyperglycaemic Emergencies

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Levemir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting with a diabetic emergency aged 18 and above. Exclusion Criteria: Patients who do not speak English and need a translator. Patients under the age of 18 years. Patients who are unable to give their consent and who do not have a relative present wiling to give assent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Levemir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to normoglycaemia |  |  | 
| Reduction of recurrence of ketoacidosis and hyperglycaemia. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate time to treatment in patients presenting with a hyperglycaemic emergency |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes emergencies
Implication of Left veNtricle Vortex Flow Guided aNticOagulation Therapy for preVenting Apical Thrombus Formation In Patients With Acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION Study

Study Overview
=================
Brief Summary
-----------------
Implication of left veNtricle vortex flow guided aNticOagulation therapy for preVenting Apical Thrombus formation In patients with acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION study

Conditions
-----------------
Apical Thrombus Formation, Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is ≥ 30 years old Acute anterior wall myocardial infarction showing akinetic or dyskinetic apical wall motion abnormalities on an initial transthoracic echocardiogram Left ventricular ejection fraction less than 40% Exclusion Criteria: Prior history of myocardial infarction Chronic medication with Coumadin Contraindication of contrast echocardiography Significant atrial or ventricular arrhythmia Valvular heart disease more than moderate degree Decompensated heart failure Very poor echo window, which cannot evaluate the presence of apical thrombus

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low risk group (A)<br>(A)Vortex depth≥0.45 | |
| High risk group 1 (B)<br>(B)Vortex depth<0.45 with anticoagulation | |
| High risk group 2 (C)<br>(C)Vortex depth <0.45 without anticoagulation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apical thrombus formation in echocardiography | Evaluate and compare the incidence of thrombus formation in high risk group (Vortex depth < 0.45) and low risk group (Vortex Depth ≥ 0.45) | 30 days after initial echocardiography | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prediction and prevention of apical thrombus formation in acute myocardial infarction patient by using Vortex parameters., Vortex, Thrombus, Contrast echocardiography
CRQ Survey Study: Clinical Research Questionnaire of Oncology Patients - A Nationwide Survey

Study Overview
=================
Brief Summary
-----------------
This is a translational, multicentre questionnaire study. The study design follows that of a cross sectional, quantitative research approach. Data collection will involve self-administered, paper-based questionnaires. The method of data collection allows for a large sample size without major expense. The questionnaires are comprised of several questions examining areas such as demographic details, cancer diagnosis, understanding of the term 'clinical trials', attitudes to personal participation in cancer clinical research and the experience of patients who previously participated in a cancer clinical trial. The study will be opened in all interested hospitals in Ireland following initiation of the study at each site. Questionnaire completion will be seen as implied informed consent and no formal consent will need to be signed by the patient. The paper-based questionnaire responses will be electronically and anonymously recorded in a computer database to facilitate analysis.

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Behavioral: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of malignancy Aged 18 years or older Ability to complete the questionnaire or independently or with the help of a friend, relative, or staff member of the oncology department Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Questionnaire|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oncology patients' understanding of the term 'clinical trials' and their attitudes towards personal participation in cancer clinical research will be evaluated by questionnaire. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The patient related factors, including level of education and socioeconomic status that influence their decision regarding participation in a cancer clinical trial (CCT) will be explored by questionnaire. |  | 1 year | 
| The patients' experience surrounding the discussion regarding CCT participation and their actual experience when enrolled in a CCT will be investigated by questionnaire. |  | 1 year |
Gait Variability in Healthy Youngs

Study Overview
=================
Brief Summary
-----------------
Three hundred healthy individuals will be participants of the study. Participants will evaluate with the following assessment tools: Demographic datas; age, gender, height, body mass, will be recorded. Gait parameters (step length, variation of step length) will evaluate with Gait trainer Biodex 2, at participant's preferred speed.

Detailed Description
-----------------
Three hundred healthy individuals will be participants of the study. Participants will evaluate with the following assessment tools: Demographic datas; age, gender, height, body mass, year, side and level of limb loss will be recorded. Gait parameters (step length, variation of step length) will evaluate with Gait Trainer Biodex 2, at participant's preferred speed. To eliminate the learning effect, participants practiced at treadmill to determine appropriate gait speed. Once participants implied the preferred speed, they asked to walk at their self selected speed for 6 minutes. Data was recorded between the 4nd and 6th minutes at walk.

Official Title
-----------------
Investigating the Gait Variability in Healthy Individuals

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Want to participate Exclusion Criteria: Have passive joint limitation at extremities Surgery at last 5 year Systemic problems such as neurologic disorders, rheumatoid disorders… Another orthopedic anomalies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Step length variability assesment while walking. |  | Initially evaluation at first minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gait variability